Details of Disease

General Information of Disease (ID: DISHIGUN)

• Disease Name: Gastrointestinal cancer
• Synonyms: stomach leiomyosarcoma; leiomyosarcoma of stomach; gastric leiomyosarcoma (disease); gastric leiomyosarcoma
• Disease Class: 2C11: Malignant digestive organ neoplasm
• Definition: An aggressive malignant smooth muscle neoplasm, arising from the stomach. It is characterized by a proliferation of neoplastic spindle cells.
• Disease Hierarchy:
  DISXGOUK: Gastric cancer
  DIS6COXM: Leiomyosarcoma
  DISHIGUN: Gastrointestinal cancer
• ICD Code:
  ICD-11: ICD-11: 2C11
  Expand ICD-11: '2C11.Z
  Expand ICD-9: 1.50E+29
• Disease Identifiers:
  MONDO ID: MONDO_0003367
  UMLS CUI: C0744295
  MedGen ID: 196652
  HPO ID: HP:0031025
  SNOMED CT ID: 447785000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Margetuximab	DMKEY6S	Approved	Antibody	[1]
Mitomycin	DMH0ZJE	Approved	Small molecular drug	[2]
Sunitinib	DMCBJSR	Approved	Small molecular drug	[3]

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CP-868596	DMZIM37	Phase 3	Small molecular drug	[4]
Napabucasin	DMDZ6Q3	Phase 3	NA	[5]
Pegargiminase	DMQKFWX	Phase 3	Recombinant protein	[5]
MLN0264	DMI4E9K	Phase 2	NA	[6]
Autologous dendritic cell-tumor cell fusion vaccine	DM8KVBW	Phase 1	NA	[7]
MEDI-565	DMFWPLQ	Phase 1	Monoclonal antibody	[8]
Minnelide 001	DM5VEN9	Phase 1	NA	[9]
RGX-202	DM8VGRX	Phase 1	Small molecular drug	[10]
Ropidoxuridine	DM6OKBJ	Phase 1	Small molecular drug	[5]
XL888	DMBKESW	Phase 1	Small molecular drug	[11]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
KA-20X	DMAROZW	Investigative	NA	[12]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8686).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5713).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7882).
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] ClinicalTrials.gov (NCT02202759) A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction. U.S. National Institutes of Health.
• [7] Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 2615.
• [8] ClinicalTrials.gov (NCT01284231) A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT01927965) Study of Minnelide in Patients With Advanced GI Tumors. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT03597581) A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT03095781) Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer. U.S. National Institutes of Health.
• [12] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.